Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025

Reuters

05/29

Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025

DALLAS-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has announced promising preclinical data for their drug candidate LP-184 in the treatment of atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer. The data was presented at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Conference held in May 2025. LP-184 has demonstrated significant anti-tumor activity across multiple ATRT cell lines and has received Rare Pediatric Disease Designation from the FDA. Lantern Pharma plans to initiate a pediatric clinical trial for LP-184 in late 2025 or early 2026, following the completion of an ongoing Phase I trial in adult solid tumors and pending necessary approvals and funding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529981828) on May 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539500582"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539500582\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539500582?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539500582","market":"us","top_or_hot":-1,"title":"Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DALLAS-- <a href=\"https://laohu8.com/S/LTRN\">Lantern Pharma Inc.</a> (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has announced promising preclinical data for their drug candidate LP-184 in the treatment of atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer. The data was presented at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Conference held in May 2025. LP-184 has demonstrated significant anti-tumor activity across multiple ATRT cell lines and has received Rare Pediatric Disease Designation from the FDA. Lantern Pharma plans to initiate a pediatric clinical trial for LP-184 in late 2025 or early 2026, following the completion of an ongoing Phase I trial in adult solid tumors and pending necessary approvals and funding.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529981828) on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-29 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DALLAS-- <a href=\"https://laohu8.com/S/LTRN\">Lantern Pharma Inc.</a> (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has announced promising preclinical data for their drug candidate LP-184 in the treatment of atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer. The data was presented at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Conference held in May 2025. LP-184 has demonstrated significant anti-tumor activity across multiple ATRT cell lines and has received Rare Pediatric Disease Designation from the FDA. Lantern Pharma plans to initiate a pediatric clinical trial for LP-184 in late 2025 or early 2026, following the completion of an ongoing Phase I trial in adult solid tumors and pending necessary approvals and funding.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529981828) on May 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL3blXCG:1","article_id":"2539500582","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539500582","pubTimestamp":1748521850,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025. DALLAS-- Lantern Pharma Inc. , a clinical-stage biopharmaceutical company, has announced promising preclinical data for their drug candidate LP-184 in the treatment of atypical teratoid rhabdoid tumors , a rare pediatric brain cancer. The data was presented at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Conference held in May 2025. LP-184 has demonstrated significant anti-tumor activity across multiple ATRT cell lines and has received Rare Pediatric Disease Designation from the FDA. Lantern Pharma plans to initiate a pediatric clinical trial for LP-184 in late 2025 or early 2026, following the completion of an ongoing Phase I trial in adult solid tumors and pending necessary approvals and funding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LTRN":"Lantern Pharma Inc."},"translate_title":"Lantern Pharma宣布LP-184治疗儿童脑癌的有希望的临床前数据，计划于2025年底进行I期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTRN":0.9},"content_text":"Lantern Pharma Announces Promising Preclinical Data for LP-184 in Pediatric Brain Cancer, Plans Phase I Clinical Trial for Late 2025\n    \n\n        DALLAS-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has announced promising preclinical data for their drug candidate LP-184 in the treatment of atypical teratoid rhabdoid tumors (ATRT), a rare pediatric brain cancer. The data was presented at the Society for Neuro-Oncology's 8th Biennial Pediatric Neuro-Oncology Conference held in May 2025. LP-184 has demonstrated significant anti-tumor activity across multiple ATRT cell lines and has received Rare Pediatric Disease Designation from the FDA. Lantern Pharma plans to initiate a pediatric clinical trial for LP-184 in late 2025 or early 2026, following the completion of an ongoing Phase I trial in adult solid tumors and pending necessary approvals and funding.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250529981828) on May 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}